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ABSTRAK
Leukemia Limfoblastik Akut (ALL) merupakan keganasan klonal di sumsum tulang/Bone Marrow (BM). Angka bertahan hidup 
5 tahun saat ini >85%, tetapi 15-20% relaps sehingga perjalanan penyakit jelek. Perjalan penyakit jelek jika setelah tahap induksi 
limfoblas menetap di Darah Tepi (DT) dan BM >5% serta tahap S BM >6%. Tahap G2/M merupakan petunjuk prognosis ALL anak, 
selain itu sebagai target pengobatan. Tujuan penelitian menganalisis kenasaban persentase tahap S dan G2/M dengan persentase 
limfoblas DT pasien ALL anak sebelum dan sesudah kemoterapi induksi. Jenis penelitian analitik observasional longitudinal (kohor) 
di ALL anak kasus baru diperiksa sebelum dan sesudah induksi. Persentase limfoblas secara mikroskopis. Persentase fase S dan G2/M 
flowcytometryBD Facs Callibur. Kenasaban bermakna hanya persentase tahap S dan limfoblas sebelum induksi (r=0,449; p=0,007). 
Kelainan gen ALL pada ekspresi cyclins dan CDK sehingga hilang kendali checkpoint siklus sel, merangsang transisi tahap G1 menjadi 
tahap S. Persentase tahap S tidak berbeda pada remisi dan meninggal (p=0,138). Persentase tahap G2/M berbeda antara remisi dan 
meninggal (p=0,006) dan bernasab dengan luaran kemoterapi induksi (koefisien Eta= 0,744), G2/M ≥1,26% meramalkan remisi. 
Terdapat kenasaban antara persentase siklus sel tahap S dengan persentase limfobas sebelum kemoterapi induksi. Persentase siklus sel 
tahap S memberikan gambaran siklus sel pada sel limfoblas. Terdapat kenasaban antara persentase siklus sel tahap G2/M dengan luaran 
kemoterapi induksi tahap G2/M menjadi faktor peramal luaran kemoterapi induksi ALL. Perlu penelitian lanjutan dengan sampel BM, 
subtipe dan pengamatan semua tahap kemoterapi.
Kata kunci: Limfoblas, siklus sel, tahap S, tahap G2/M, ALL
ABSTRACT
Acute Lymphoblastic Leukemia (ALL) is a Bone Marrow (BM) clonal malignancy. At the moment, the five year survival rate is 
>85%, 15-20% relapse showing a bad prognosis. Persistant Peripheral Blood (PB) lymphoblasts, BM >5%, S phase BM >6% after 
induction give a poor prognosis. G2/M phase is an indicator for the prognosis and treatment target in ALL. The research aimed 
to analyze the correlation percentage of S phase and G2/M with the percentage of PB lymphoblasts in pediatric ALL patients 
before and after chemotherapy induction. This was an analytical observational longitudinal (cohort) research in new pediatric ALL 
cases, examined before and after induction. Percentage of lymphoblasts was examined microscopically, percentage of S phase and 
G2/M by flowcytometry BD FacsCallibur. A significant correlation was only found in the percentage of S phase and lymphoblasts 
before induction(r=0.449; p=0.007). ALL gene abnormalities were in the expression of cyclins and CDKs causing loss of control 
checkpoint, stimulating G1 phase transition into S phase. Percentage of S phase did not differ between remission and who died 
(p=0.138). Percentage of G2/M phase differed between remission and who died (p=0.006) and correlated with outcomes (coefficient 
Eta=0.744). G2/M ≥1.26% predicting an increased remission. There was a correlation between the percentage of cell cycle S phase 
and percentage of lymphoblasts before chemotherapy induction. The percentage of S phase gave an overview of lymphoblasts cell 
cycle. There was a correlation between G2/M phase percentages with chemotherapy induction outcomes. G2/M was a predictive 
factor for ALL chemotherapy induction outcomes. A further research is needed with BM samples, subtypes and observation of all 
phases of chemotherapy.
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INTRUDUCTION
Acute Lymphoblastic Leukemia (ALL) is a malignant 
(clonal) disease of the bone marrow in which early 
lymphoid precursors proliferate and replace the 
normal hematopoietic cells of the marrow.1 Acute 
lymphoblastic leukemia is a common malignancy in 
the United States, the most common age is 1–4 years 
and occurance in males (45–55%) is more common 
than females.2 A previous research in the Dr. Soetomo 
Hospital reported that there were 82 pediatric ALL new 
cases with outcomes after induction phase as remission 
48.5%, no remission 14.7% and died 36.8%.3 The five 
year survival rate for the last  decade was 90.4% but 
about 15-20% relapsed.4 
Prognosis in ALL is inf luenced by several 
parameters such as age, number of leucocytes, cell 
morphology immunophenotype and genotype. Blast 
clearence speed in the peripheral blood during 
therapy is a prognostic factor in the outcome of 
pediatric ALL.5 A research by Posadzy et al6 found 
out that lymphoblast Peripheral Blood (PB) which 
settled after one week and bone marrow >5% after 
induction chemotherapy gave a poor prognosis.6 Early 
clearance of peripheral blood blasts after induction 
chemotherapy predicts early marrow blast clearance, 
complete remission, Relapse-Free Survival (RFS) and 
Overall Survival (OS).7 S phase of the cell cycle can be 
a prognostic value in acute leukemia. Kumar8 stated 
that it was low, S phase <2.6% before chemotherapy 
and > 6% after chemotherapy induction phase gave a 
poor response to induction chemotherapy and required 
intensive chemotherapy.8 Cell cycle G2/M phase was 
related to the outcome of chemotherapy induction. A 
high fraction was corelated with poor outcomes in ALL 
patients. G2/M phase was the target of chemotherapy 
drugs so it could stimulate an apoptotic signal and 
induce apoptosis of cancer cells.9 
Currently, there is no research on the correlation of 
the S phase percentage of the cell cycle and G2/M with 
the percentage of lymphoblast cells in peripheral blood 
in pediatric ALL in the Dr Soetomo Hospital.
The cell cycle is the sequence of events of cell 
growth and division into two cells. Cell cycle is divided 
into four stages, G1-S-G2-M. Cell cycle begins with 
the activation of cyclin D-CDK4/6 is and controlled by 
CDK inhibitor to activate the checkpoint signals so that 
cells stop proliferating. The DNA damage also activates 
signals checkpoint so the cell has time to repair DNA 
damage. Cell cycle abnormalities in ALL is on p 53 
expression causing malfunction of CDK inhibitors and 
the cell can not stop proliferation if there is a stimulus 
checkpoint and results in uncontrolled proliferation.10 
Lekemic cells have a high proliferation compared to 
normal cells.11
The purpose of this study was to analyze the 
correlation between the percentage of cell cycle phases 
S and G2/M with the percentage of lymphoblasts 
in the peripheral blood before and after induction 
chemotherapy and the clinical benefit was to use 
the percentage of S and G2/M for stratification and 
predicting induction chemotherapy outcomes in 
pediatric ALL patients.
METHODS
This research was an observational analytical 
design with longitudinal (cohort), from March to June 
2016. Sampling in the Outpatient Clinic and patient 
wards of the Department of Pediatrics Hemato-
Oncology and sampling examination was performed 
in the Clinical Pathology Laboratory, Dr. Soetomo 
Hospital.
Inclusion criteria samples were ALL patients 
aged 1 month–16 years old who underwent regular 
chemotherapy, received the approval of the parents/
guardians. Exclusion criteria were ALL patients 
with congenital abnormalities complex, multi-organ 
abnormalities, withdrawal from study participation.
Examination of the percentage of cell cycle was 
by using flowcytometry BD FACS Callibur with 
Propidium Iodine (PI) dyes. Microscopic examination 
of lymphoblast percentage with Wright staining. 
Statistical analysis for the difference in the percentage 
of cell cycle phases S and G2/ M with a percentage 
of lymphoblasts was done by t-test 2 samples and 
Wilcoxon Signed Rank, correlation of the percentage 
of cell cycle phases S and G2/M with a percentage of 
lymphoblasts with Pearson and Spearman correlation 
test, the difference between phase S and G2/M in 
induction chemotherapy outcomes used the Mann-
Whitney U Test and correlation of cell cycle phase with 
induction chemotherapy outcomes with correlation Eta 
test.
RESULTS AND DISCUSSION
Total samples were 35 new pediatric ALL patients 
before chemotherapy then followed until completion 
induction phase of chemotherapy. The final subjects 
were 20 patients. Characteristics of the samples 
consisted of gender and age (can be seen in Table 1).
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Research subjects were mostly males 18 (51.4%). 
This result was the same with Sandeep et al12, 55 % 
males and 45% females. The high male incidence was 
correlated with the Single Nucleotide Polymorphism 
(SNP) that activated enhancers or activated promoter 
regions and had regulatory effects on gene expression 
levels, this gene may counteract the suppressor effect 
of estrogen-regulated in males.12
Most of these research subjects were 2-5 years 
(45.71%). These results were the same with Ugrasena 
et al3, who also found that the age was 2-5 years in 
pediatric ALL patients. The age had a twice lower risk 
of death compared with below 2  years. This age was 
more common in type B ALL.2,12
Examination results of hemoglobin, leukocytes, 
platelets, the percentage of cell cycle and the 
percentage of lymphoblasts, can be seen in Table 2.
The mean Hb before induction chemotherapy was 
8.73 g/dL. The cause of anemia can be caused due to 
the effects of a chronic disease, specific nutritional 
deficits, chronic bleeding, neoplastic infiltration of 
the BM, intercurrent, infections and autoimmune 
hemolytic processes. A new research found that 
reduced erythropoiesis was the other cause of anemia 
because of molecular changes in the regulation of cell 
growth in the bone marrow micro-environment.13,14
Table 1. Characteristics of research subjects
Characteristics of research 
subjects
f (%)
Gender
Male
Female
18 (51.4%)
17(48%)
Age
Mean ± SD
< 2 years
2-5 years
6 – 9 years
>10 years
5.75 ± 3.73
4 (11.43%)
16 (45.71%)
8 (22.86%)
7 (20 %)
Table 2. Results of examination on hemoglobin, total leukocytes, platelets, S phase, G1 phase, phase G2/M and S phase ALL 
children patients before and after induction therapy
Parameter
Pre induction (n=35) Post induction (n=20)
p
⎯x ± SD Min-Max ⎯x ± SD Min-Max
Hb (g/dL) 8.73±2.77 4.00–14.40 10.37±1.68 7.00–13.20 0.358
Leukocytes 
(10³ /μL)
89.40±166.76 1.85–67.00 6.64±1.97 3.60–10.00 0.244
Platelets
(10³ /μL)
84.26±71.81 11.00–312.00 131.91± 65.28 70.00–254.00 0.002
Lymphoblasts (%) 18.37±21.87 0.00–80.00 0.00±0.00 0.00–0.00 0.000
G1(%) 92.60±5.47 70.56–98.55 94.34±6.21 72.78–99.33 0.063
G2/M (%) 1.14±1.82 0.00–7.19 0.86±1.64 0.00–7.36 0.113
S (%) 6.26±5.71 1.42–29.02 4.80±5.54 0.45–25.88 0.092
This research obtained 8 (22.86%) with leukocytes 
> 100 x10³/μL and 4 (11.43%) < 3x10³/μL. Acute 
lymphoblastic leukemia represented a group of 
B/T-precursor-stage lymphoid cell malignancies 
arising from genetic alterations that block lymphoid 
differentiation and drive aberrant cell proliferation 
and survival. When this happens, white blood cell 
production becomes abnormal and increases the 
number of white blood cell.15
The mean platelet count before induction 
chemotherapy was 84.26 x10³/μL. Low platelets are 
an indication for lymphoblast cell infiltration in the 
bone marrow progenitor and causing suppression of 
megakaryocytes.5
Average lymphoblast PB was 18.37% in pre-
induction chemotherapy, different from the research of 
Rashmi et al5, with the average percentage of 87.3%. 
The difference was due to lymphoblast percentage 
variation in this study.5 Percentage of lymphoblast after 
induction chemotherapy was 0%. This was similar to 
Rashmi5 reporting, the percentage of lymphoblast after 
induction chemotherapy as 0.7%. Total lymphoblast PB 
would disappear in <10 days and would give a better 
prognosis. Pheripheral blood blast was negative in 6 
days and predicted a reduction in BM blast occuring on 
day 14, which predicted complete remission.7 
The mean and median percentage of S phase before 
induction chemotherapy were 6.26% and 4.45, this 
result was different from Kumar8, who found that in 
type B ALL, the mean and median were 2.6% and 
2.3%. The difference in the results of this study with a 
previous research was due to differences in sampling 
time, age and type of ALL which in this study did not 
distinguish the type. Patients with B type ALL had a 
more lower S phase cell cycle.8 
Induction of chemotherapy outcomes in this study 
were mostly in remission 21 (60%) Table 3.
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This research result was different with Ugrasena et 
al in 2010, who reported that the remission was 40.9% 
and 48.5%. Remission rates improved more as time 
goes because protocols had been developed and the 
latest regimen was used in ALL chemotherapy.3
There was a significant correlation between 
the percentage of S phase and the percentage of 
lymphoblast before induction chemotherapy (r= 0.449; 
p=0.007) Figure 1. 
Detection of a damage that were activated in 
normal hemotopoesis cells, the Ataxia-Telangiectasia 
Mutated (ATM) played a central role in the activation 
of the G1/S cell cycle checkpoint, preventing cells with 
damaged DNA from starting the S phase.16 There was 
an abnormality in activity of ALL checkpoint. The 
gene abnormality that caused expression of cyclins 
and Cyclin-Dependent Kinases (CDKs) disrupted so it 
could make a loss of cell cycle checkpoint control. The 
gene abnormalities stimulated the G1 phase cell cycle 
Table 3. Induction chemotherapy outcomes results
Outcomes Frequency %
Dead 14 40.0
Remission 21 60.0
Figure 1. Graphic correlation percentages of G2/M phase and percentage lymphoblasts in peripheral blood before chemotherapy induction 
of pediatric acute lymphoblastic leukemia
transition into phase S. The proportion of cell cycle 
phases in leukemic cells was mostly in the S phase. The 
S phase could represent leukemic cell proliferation.17
There was no significant correlation between 
the percentage of G2/M phase and the percentage 
of lymphoblasts (r=-0.306; p=0.074) before 
chemotherapy (figure 2). The percentage of phase 
S and G2/M with percentage of lymphoblasts after 
induction chemotherapy could not be analysed because 
the percentage of lymfoblasts after chemotherapy was 
0%.
Statistical analysis found no difference in outcomes 
according to the S phase after induction chemotherapy 
(p=0.138), Table 4. This result showed that the S phase 
could not be used to predict induction chemotherapy 
outcomes. This result differed with Kumar 2015, where 
S phase could be used to predict relapse. Percentages 
of S phase > 4% patient tended to relapse, relapse of 
patients was usually because of an increasing activity 
of proliferation in bone marrow that made the cell 
turnover and cell leukemic production increase. 
Increasing proliferation can be caused in effective 
chemotherapy and drug resistance.8 The difference 
was because this research was performed only 
until induction phase, the first phase of sequences 
Figure 2. Graphic correlation percentages of G2/M phase and percentages of lymphoblasts before induction chemotherapy  
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of chemotherapy in ALL and the difference in total 
leukemic cells in S phase. 
There was a difference in G2/M phase between 
outcomes of induction chemotherapy (p=0.006). G2/M 
phase was correlated to remission outcomes, with 
coefisient Eta result was p=0.744. 
The G2 /M phase can be used for prognosis in 
pediatric ALL. This research showed that G2/M was 
>1.26%, the changes for remission were more higher. 
Leukemic cell in G2/M phase after treated with 
chemotherapy agent underwent death following mitotic 
arrest.18 This research also showed that the G2/M 
phase < 1.26% predicted poor outcomes. The reason 
was because the chemotherapy agent for specific cell 
cycle Mitotic phase could not be effective, only cells 
that enter mitosis are killed or rendered senes cent. 
Quiescent cells (cells that are in a temporary state of 
not dividing) or cycling cells that do not reach mitosis 
during drug exposure are spared.19
CONCLUSION AND SUGGESTION 
In this research there was a correlation between 
percentages of S phase and percentages lymphoblasts, 
so S phase can be used as a picture of proliferation in 
lymphoblasts. There was a correlation between G2/M 
with the remission patients. This phase can be use as 
predictor for induction chemotherapy outcomes.
Futhers research must be done with bone marrow 
samples, determining the cluster differentiation, 
examinating the lymphoblast in several days and 
examination in all phase chemotherapy.
Table 4. Statistical analysis result in differences percentages of S phase cell cycle between induction chemotherapy outcomes in 
all pediatric patients
Outcomes n
Persentages S phase
p
⎯x SD Minimum Maximum
Remission 21 5.50 5.98 1.42 29.02
0.138
Dead 14 7.39 5.29 1.86 23.22
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